PAINS-killer: UNC study finds serious issues with popular drug screening tool

July 11, 2017

A widely used screening tool deployed in the early phases of drug discovery to weed out undesirable compounds is wrong so often it can't be trusted on its own, according to scientists at the University of North Carolina at Chapel Hill.

PAINS -- or pan-assay interference compounds --are a prominent source of false positives in the drug-discovery process. PAINS are biologically active compounds that masquerade as potential drug candidates during the initial high volume screening used to search for possible new drugs. PAINS work by disrupting the assay technology used in the screening to report biological activity, but they are not active against the intended biological target.

Seven years ago, a team of scientists identified a set of a molecular fingerprints that they said could be used to identify PAINS compounds. They found 480 molecular fragments they called PAINS alerts. The presence of a PAINS alert in a compound meant the compound was a PAIN. Pharmaceutical scientist were grateful to finally have an easy-to-use tool to filter PAINS out of the drug discovery process. Not so fast, says Alex Tropsha, Ph.D., the K.H. Lee Distinguished Professor at the UNC Eshelman School of Pharmacy.

His team, led by graduate student Stephen Capuzzi, took a hard look how the 480 PAINS alerts were developed. They found that 328 of the alerts -- almost 70 percent -- were created from just four or fewer compounds each. No viable conclusions should be made from such small samples, Capuzzi said.

"In some cases, just one compound with a certain substructure exhibited bad behavior, and then an alert was created. In the PAINS screening tool, that alert gets applied to everything with a similar structure," Capuzzi said. "It's like someone who was bitten by a dog named Fido assuming that every dog named Fido is dangerous."

The UNC-Chapel Hill researchers analyzed thousands of compounds that have been tested in hundreds of experiments and showed that majority of compounds flagged with PAINS alerts do not exhibit any tendency to interfere with drug-candidate screening technology and may in fact be consistently inactive despite extensive testing.

"PAINS are real, and they're a real problem for medicinal chemists who might be screening tens of thousands of compounds a day looking for a drug candidate," Tropsha said. "However, PAINS alerts flag vast numbers of good compounds as PAINS. We also found that the presence of PAINS alerts, contrary to expectations, did not reflect any heightened activity during the assay process."

When challenging a popular idea like PAINS alerts, the UNC-Chapel Hill researchers had to be sure they were right in saying the system is critically flawed so they tested their idea extensively.

First, they analyzed thousands of compounds in a publicly available database of thoroughly tested chemicals and showed that many compounds that possess PAINS substructures do not actually appear to interfere with drug-screening technology.

Next, the team applied PAINS filters to a group of chemical compounds known as dark chemical matter. The compounds in this group have all been tested more than 100 times each without showing any biological activity. They, by definition, should not contain any PAINS alerts because PAINS are biologically active, but the UNC team found 109 PAINS alerts present in 3,570 dark chemical matter compounds reviewed.

Finally, UNC and other researchers have also observed that 87 FDA-approved drugs, including 19 from the World Health Organization List of Essential Medicines, contain PAINS alerts. One example is zidovudine, which is used to prevent and treat HIV/AIDS. Between 2008 and 2011, zidovudine was prescribed over 1 million times in the U.S. alone.

Eltrombopag, an FDA-approved breakthrough treatment for thrombocytopenia, or low platelet count, contain PAINS alerts. So does Tadalafil, better known as Cialis, which has annual sales topping $2 billion and is approved to treat both erectile dysfunction and enlarged prostate.

"People have been blindly using PAINS alerts, and if they continue to do so, many much-needed drugs may never be found," Tropsha said. "Computational tools can aid in the triage process for finding new drug compounds, but if they're used inappropriately or without caution, the same tools may prevent future drugs from ever making it to market."

Tropsha's group continues to work on computational approaches that will reliably predict possible drug candidates while eliminating unlikely drug candidates from further consideration. Their study was published in the ACS Journal of Chemical Information and Modeling and was selected as an ACS Editors' Choice Article.

University of North Carolina at Chapel Hill

Related Drug Discovery Articles from Brightsurf:

December special issue of SLAS Discovery features 'drug discovery targeting COVID-19'
The December edition of SLAS Discovery, ''Drug Discovery Targeting COVID-19'' is a special collection assembled by Associate Editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts toward the current global pandemic of COVID-19caused by the novel coronavirus, SARS-CoV-2.

New cell profiling method could speed TB drug discovery
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis.

An open-access tool to accelerate drug discovery
The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules.

New macrolactone database could aid drug discovery, research
Researchers have created a free-to-use database of 14,000 known macrolactones -- large molecules used in drug development -- which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.

Discovery of a drug to rescue winter depression-like behavior
A group of animal biologists and chemists at the Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, has used a chemical genomics approach to explore the underlying mechanism of winter depression-like behavior and identified a drug that rescues winter depression-like behavior in medaka fish.

Fat-fighting drug discovery
Cancer-fighting compound fights obesity and diabetes.

New cell models for ocular drug discovery
Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.

Machine learning's next frontier: Epigenetic drug discovery
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images -- allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more.

Discovery of how colorectal cancer drug works will help more patients
Some colorectal cancer patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.

Speeding up the drug discovery process to help patients
An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

Read More: Drug Discovery News and Drug Discovery Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to